The Korea Disease Control and Prevention Agency (KDCA) has designated additional rare disease specialist institutions to strengthen regional healthcare and reduce disparities. This policy is part of national agenda item 86-3, which focuses on easing the burden of rare and intractable diseases and reinforcing state responsibility for conditions such as type 1 diabetes. The expansion aims to ensure that patients can receive comprehensive services—from diagnosis to ongoing management—close to their homes. The specialist institutions serve as regional hubs, collecting data, providing genetic counseling, and supporting patient education.
Patients with rare diseases, their families, and healthcare professionals in previously underserved regions are the primary beneficiaries of this policy. The specialist centers offer integrated medical services, including registration statistics, genetic counseling, medical expense support, and patient education programs. In 2024, 17 institutions handled 46.6% of rare disease cases among 354,000 patients at 361 hospitals, and 61% of cases at advanced general hospitals. The new designations in Gwangju (Chonnam National University Hospital) and Ulsan (Ulsan University Hospital) address previous gaps in these regions.
The policy was implemented on March 30, 2024, with the addition of two new specialist centers. The KDCA plans to gradually designate centers in remaining regions (Gyeongbuk and Chungnam) by 2027 to achieve nationwide coverage. The selection process evaluated institutions based on their capacity, compliance with designation requirements, and ability to serve local needs. The expansion is expected to provide timely and patient-centered care, reducing the need for patients to travel outside their region.
Frequently asked questions include: What services do rare disease specialist institutions provide? They offer diagnosis, treatment, genetic counseling, medical expense support, and patient education. How will the expansion impact patients? It will enable more convenient access to comprehensive care in their local area. What is the timeline for full nationwide coverage? The KDCA aims to designate centers in all regions by 2027, with Gwangju and Ulsan added in March 2024.
Metaqsol opinion: The expansion of rare disease specialist institutions in Korea is a strategic move to close regional healthcare gaps and improve outcomes for patients and families. The addition of centers in Gwangju and Ulsan ensures that more individuals can access diagnosis, treatment, and ongoing management without leaving their home region. The policy’s focus on genetic counseling and patient education is especially valuable for rare disease patients. The gradual rollout through 2027 reflects a thoughtful approach to achieving nationwide coverage and balanced care.